Showing results (1-10 of 244) with videos related to
Sort By:
Pageof 25
Clinical Pharmacology and Therapeutics|August 1, 1986
Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrineG Carrum, J M Egan, D R AbernethyPharmacology|January 1, 1988
Effects of nifedipine on hepatic drug oxidationT H Dickinson, J M Egan, D R AbernethyClinical Pharmacology and Therapeutics|May 1, 1987
The effect of propylene glycol on antipyrine clearance in humansE B Nelson, J M Egan, D R AbernethyThe Journal of Pharmacology and Experimental Therapeutics|March 1, 1988
Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humansD R Abernethy, J M Egan, T H Dickinson, et al.The American Journal of Cardiology|September 15, 1987
Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertensionD R Abernethy, J B Schwartz, J R Plachetka, et al.Geriatric Nephrology and Urology|August 6, 1999
Aging effects on drug disposition and effectD R AbernethyDrug Safety|January 1, 1990
Research challenges, new drug development, preclinical and clinical trials in the ageing populationD R AbernethyClinics in Geriatric Medicine|May 1, 1990
Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patientsD R AbernethyThe American Journal of Cardiology|August 21, 1997
Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonistD R AbernethyThe American Journal of Cardiology|January 27, 1994
An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertensionD R AbernethyPageof 25